The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible Medicare Part D beneficiaries for $50 per month beginning July 1 this year through Dec. 31, 2027. The program will be conducted under the agency’s short-term demonstration, the Medicare GLP-1 Bridge. The demonstration is tied to CMS’ Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth Model, or BALANCE, which is designed to increase access to GLP-1 medications and other healthy lifestyle interventions.

Headline
The Centers for Medicare & Medicaid Services announced that it will exercise enforcement discretion for inpatient rehabilitation facility admissions from…
Headline
The Centers for Medicare & Medicaid Services has released 2027 Medicare Advantage plan information, including star ratings, through the Medicare Plan…
Headline
The AHA provided comments to the Medicare Payment Advisory Commission Oct. 2 on a discussion from the commission’s September meeting on its examination of…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 25 that it will expand the Inpatient Rehabilitation Facility Review Choice Demonstration to…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services Sept. 15 announced an expansion of its outcome-aligned payment model offering technology-supported care to…